Risperdal news from FiercePharma
NewsJ&J fights Teva with generic Risperdal
It's a watershed moment: Risperdal has gone generic. The Johnson & Johnson antipsychotic med now has copycat competition from Teva Pharmaceutical Industries, which got the final FDA go-ahead... Read more...
Emerging markets drive global growth
Without emerging healthcare markets like China and India, global pharma would be in a world of hurt. The global market for meds reached $712 billion last year, according to a new report from IMS... Read more...
ALSO NOTED: FDA announces generic Risperdal, then retracts; Botox maker probed for off-label marketing
> The FDA announced that it had approved Ranbaxy's version of the Johnson & Johnson antipsychotic Risperdal--only the Indian firm hadn't applied. The agency quickly issued a retraction;... Read more...
ALSO NOTED: MedImmune acquisition could pay dividends; Sun challenges J&J patent;
> Analysts say AstraZeneca's buyout of MedImmune could pay extra dividends as health officials expand their recommendations for an flu jab to all children between the ages of six months and 18.
Arkansas sues J&J over Risperdal
Atypical antipsychotics are back in the news today: the Arkansas attorney general has filed suit... Read more...
'Atypicals'still sell big in nursing homes
Here's something we've been wondering: How much does a black-box warning affect drug sales? According to a story in the St. Petersburg Times today, not much, at least not for the atypical... Read more...
Bristol's Abilify gets nod for adolescents
Better late than never, Bristol-Myers Squibb might say. In a move that's sure to incite debate, the FDA says it will allow BMS to market its schizophrenia med Abilify for use in adolescents. The... Read more...
Pharma growth sinking to historic low
Here's statistical confirmation of the gloom-and-doom facing Big Pharma. Worldwide sales growth will slow next year to around 5... Read more...
Study: 86% of docs cut Zyprexa use
Whoever said there's no such thing as bad publicity never worked in pharma. The latest proof of bad news-related suffering: A new report on antipsychotic drugs finds Janssen's Risperdal and... Read more...
Risperdal OK'd for children
It might sound like a candidate for the So What? award, but the FDA's approval of the "atypical" antipsychotic Risperdal for use in children and adolescents is a landmark decision. The... Read more...
| Press ReleasesFDA Issues Approvable Letter for RISPERDAL® to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar MaFDA Issues Approvable Letter for RISPERDAL® to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania Titusville, NJ. June 21, 2007 - Johnson & Johnson Read more >> PRESS RELEASE: FDA Approves RISPERDAL to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania TITUSVILLE, N.J., Aug. 22 -- The U.S. Food and Drug Administration Read more >> |
Get more Risperdal coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
